Catalent, Inc.





Market Closed - Nyse 21:00:02 18/06/2024 BST 5-day change 1st Jan Change
55.07 USD -0.25% Intraday chart for Catalent, Inc. -1.33% +22.57%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Catalent Shareholders Approve Deal With Novo Holdings MT
Catalent stockholders approve deal with Novo Holdings RE
Argus Downgrades Catalent to Sell From Buy MT
Novo Nordisk Selling $5 Billion in Bonds to Back Catalent Deal MT
Novo Nordisk Plans First Bond Sale in Two Years MT
Novo Nordisk Plans First Bond Sale in 2 Years MT
MOVES -Lazard hires veteran healthcare dealmaker Colocci as vice chairman RE
Earnings Flash (CTLT) CATALENT Posts Q3 Revenue $1.07B MT
Catalent, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer CI
Top Midday Stories: Apple's Dividend, Buybacks Announcements; Amgen Obesity Drug Trial Results; Exxon Completes Pioneer Acquisition MT
Catalent, Novo Nordisk Antitrust Review Extended by FTC MT
FTC Seeks More Info On $16.5 Billion Novo/Catalent Deal DJ
US FTC seeks more information on Novo Nordisk parent-Catalent deal RE
FTC seeks more information on Novo Holdings-Catalent deal RE
Obesity drugmaker Novo Nordisk raises outlook, Q1 profit beats forecast RE
Obesity drugmaker Novo Nordisk's Q1 profit beats forecast RE
Zacks Investment Research Downgrades Catalent to Underperform From Neutral, Price Target is $48 MT
Sector Update: Health Care Stocks Decline Late Afternoon MT
Sector Update: Health Care Stocks Flat to Higher Premarket Monday MT
Novo Nordisk Parent Resubmits US Antirust Application for Catalent Acquisition MT
Novo Nordisk parent refiles US application on Catalent deal RE
Novo Nordisk owner refiles U.S. application for approval of Catalent deal RE
Invenra Inc. Announces Strategic Collaboration with Catalent to Co-Discover Novel Bispecific ADCs CI
Novo Nordisk hopes to launch experimental obesity drug this decade RE
Chart Catalent, Inc.
More charts
Catalent, Inc. is specialized in pharmaceutical outsourcing services. The group offers solutions for the development and formulation of drugs, biological products and animal health products. Net sales break down by activity as follows: - provision of development services and clinical supply services (55.4%); - subcontracted manufacturing services (44.6%). Net sales are distributed geographically as follows: the United States (63.2%), Europe (28.7%) and other (8.1%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
55.07 USD
Average target price
63.5 USD
Spread / Average Target
  1. Stock Market
  2. Equities
  3. CTLT Stock
  4. News Catalent, Inc.
  5. Catalent Shareholders Approve Deal With Novo Holdings
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.